A macromolecular multicomponent peptide vaccine prepared using the glutaraldehyde conjugation method with strong immunogenicity for HIV-1. NLM AIDSLINE Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


A macromolecular multicomponent peptide vaccine prepared using the glutaraldehyde conjugation method with strong immunogenicity for HIV-1.

Clin Immunol Immunopathol. 1995 Dec;77(3):374-9. Unique Identifier : AIDSLINE MED/96080367
Hamajima K; Bukawa H; Fukushima J; Kawamoto S; Kaneko T; Sekigawa K; Tanaka S; Tsukuda M; Okuda K; Department of Bacteriology, Yokohama City University School of; Medicine, Japan.

Abstract: The immunogenicity of a newly constructed macromolecular multicomponent peptide vaccine candidate against human immunodeficiency virus type 1 (HIV-1) was compared with that of previously reported vaccine candidates. This vaccine candidate is composed of a macromolecular multicomponent peptide complex consisting of three V3 region peptides, one Gag region peptide, and CD4-binding site peptide and was constructed using the multiple-antigen peptide and glutaraldehyde methods. Sera from rabbits immunized with this newly constructed vaccine showed strong antibody titers against each constituent peptide antigen. Furthermore, these antibodies exhibited strong neutralizing and antifusion activity toward HIV-1IIB, HIV-1MN, and fresh isolates from Japanese HIV-seropositive individuals. These results show that this new vaccine candidate has the capacity to induce strong, polyvalent immunogenicity and therefore may prove to be a powerful peptide vaccine against HIV-1 infection.
Keywords: Amino Acid Sequence Animal AIDS Vaccines/*IMMUNOLOGY Enzyme-Linked Immunosorbent Assay Glutaral/*PHARMACOLOGY Human HIV Antibodies/BIOSYNTHESIS HIV Antigens/CHEMISTRY/IMMUNOLOGY/PHARMACOLOGY HIV-1/*IMMUNOLOGY Molecular Sequence Data Neutralization Tests Rabbits Support, Non-U.S. Gov't Vaccines, Synthetic/CHEMISTRY/DRUG EFFECTS/*IMMUNOLOGY JOURNAL ARTICLEKWDaminoacidsequenceanimalaidsvaccines/KWDimmunologyenzyme-linkedimmunosorbentassayglutaral/KWDpharmacologyhumanhivantibodies/biosynthesishivantigens/chemistry/immunology/pharmacologyhiv-1/KWDimmunologymolecularsequencedataneutralizationtestsrabbitssupport,non-uKWDsKWDgov'tvaccines,synthetic/chemistry/drugeffects/KWDimmunologyjournalarticle
960228
M9620717

Copyright © 1996 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .